720 related articles for article (PubMed ID: 22717676)
41. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N
Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760
[TBL] [Abstract][Full Text] [Related]
42. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
43. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
44. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
[TBL] [Abstract][Full Text] [Related]
45. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
46. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
Demarchi F; Brancolini C
Drug Resist Updat; 2005 Dec; 8(6):359-68. PubMed ID: 16406769
[TBL] [Abstract][Full Text] [Related]
47. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
48. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
50. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
[TBL] [Abstract][Full Text] [Related]
51. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
52. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Neukirchen J; Meier A; Rohrbeck A; Garcia-Pardillos G; Steidl U; Fenk R; Haas R; Kronenwett R; Rohr UP
Cancer Gene Ther; 2007 Apr; 14(4):431-9. PubMed ID: 17235352
[TBL] [Abstract][Full Text] [Related]
53. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
54. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
[TBL] [Abstract][Full Text] [Related]
55. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
[TBL] [Abstract][Full Text] [Related]
56. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
57. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
[TBL] [Abstract][Full Text] [Related]
58. The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.
Fontanini A; Foti C; Potu H; Crivellato E; Maestro R; Bernardi P; Demarchi F; Brancolini C
J Biol Chem; 2009 Mar; 284(13):8369-81. PubMed ID: 19139105
[TBL] [Abstract][Full Text] [Related]
59. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
[TBL] [Abstract][Full Text] [Related]
60. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
